240 related articles for article (PubMed ID: 34551663)
1. Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M; Puzzoni M; Ziranu P; Pusceddu V; Lai E; Pretta A; Donisi C; Pinna G; Spanu D; Cimbro E; Parrino A; Liscia N; Mariani S; Dubois M; Migliari M; Scartozzi M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1253-1264. PubMed ID: 34551663
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
5. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
6. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
7. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
8. Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
[No Abstract] [Full Text] [Related]
9. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
10. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Mayr C; Kiesslich T; Modest DP; Stintzing S; Ocker M; Neureiter D
Expert Opin Investig Drugs; 2022 Feb; 31(2):221-233. PubMed ID: 35098846
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
14. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D; Ferté C
Eur J Cancer; 2017 Aug; 81():161-173. PubMed ID: 28628842
[TBL] [Abstract][Full Text] [Related]
15. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
[TBL] [Abstract][Full Text] [Related]
17. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
18. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Athauda A; Fong C; Lau DK; Javle M; Abou-Alfa GK; Morizane C; Steward K; Chau I
Cancer Treat Rev; 2020 Jun; 86():101998. PubMed ID: 32203843
[TBL] [Abstract][Full Text] [Related]
19. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
Demols A; Bucalau AM; Mans L
Curr Opin Oncol; 2022 Jul; 34(4):403-411. PubMed ID: 35837710
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
